ID: h-db6058d23e
Hypothesis
Glucosylceramide-mediated feedback loop drives GBA-synuclein pathology
In GBA-associated PD, reduced glucocerebrosidase activity leads to glucosylceramide accumulation in neurons and glia, which directly promotes α-synuclein fibrillization by stabilizing toxic oligomers and disrupting membrane curvature.
neurodegeneration
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
In GBA-associated PD, reduced glucocerebrosidase activity leads to glucosylceramide accumulation in neurons and glia, which directly promotes α-synuclein fibrillization by stabilizing toxic oligomers and disrupting membrane curvature. These α-synuclein aggregates subsequently traffic to the lysosome where they inhibit wild-type GBA activity and impair ER-Golgi trafficking of new GBA enzyme, creating a feedforward loop. I hypothesize that pharmacological restoration of GBA activity using allosteric activators (not chaperones) will preferentially reduce glucosylceramide levels, disrupting this loop and reducing α-synuclein seeding capacity in patient-derived neurons.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["GBA1 Variant<br/>Glucosylceramide Metabolism"]
B["Feedback Loop<br/>GBA-Synuclein Pathology"]
C["Lysosomal<br/>Dysfunction"]
D["Alpha-Synuclein<br/>Aggregation"]
E["GBA1 as<br/>Feedback Loop Target"]
F["Glucosylceramide<br/>Homeostasis Restoration"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports0 contradicts
Supports
Classification of GBA1 Variants in Parkinson's Disease: The GBA1-PD Browser.
Supports
Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease.
Supports
Gene Therapy for Parkinson's Disease Associated with GBA1 Mutations.
Supports
A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator.
Supports
The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — GBA1
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for GBA1 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for GBA1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.1040
Events (7d)
0
Price History
▲8.4%💾 Resource Usage
LLM Tokens
15,800
$0.0948
Total Cost
$0.0948
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF primary cortical neurons derived from GBA-PD patient iPSCs are treated for 14 days with a selective allosteric GBA activator (not a pharmacological chaperone) at doses sufficient to restore enzyme | Glucosylceramide reduction correlates inversely with α-synuclein seeding capacity; temporal ordering confirms upstream lipid accumulation driving aggregation ra | — no observation — | pending | 0.65 |
| IF cerebrospinal fluid glucosylceramide concentrations are measured and α-synuclein seeding activity is assessed via αSyn-SAA in a cohort of ≥80 GBA-PD patients stratified by genotype severity (severe | Stratified correlation between glucosylceramide and seeding activity specific to GBA-PD genotype severity, supporting glucosylceramide as a quantitative driver | — no observation — | pending | 0.58 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF primary cortical neurons derived from GBA-PD patient iPSCs are treated for 14 days with a selective allosteric GBA activator (not a pharmacological chaperone) at doses sufficient to restore enzyme activity to ≥70% of wild-type levels, THEN both glucosylceramide levels and α-synuclein seeding acti
Predicted outcome: Glucosylceramide reduction correlates inversely with α-synuclein seeding capacity; temporal ordering confirms upstream lipid accumulation driving aggr
Falsification: If allosteric GBA activation reduces glucosylceramide by ≥40% but α-synuclein seeding activity remains unchanged or increases, the glucosylceramide-to-aggregation pathway is not direct and this hypoth
pendingconf 58%
IF cerebrospinal fluid glucosylceramide concentrations are measured and α-synuclein seeding activity is assessed via αSyn-SAA in a cohort of ≥80 GBA-PD patients stratified by genotype severity (severe: null/null or compound heterozygous; mild: N370S heterozygous) and compared to ≥40 idiopathic PD an
Predicted outcome: Stratified correlation between glucosylceramide and seeding activity specific to GBA-PD genotype severity, supporting glucosylceramide as a quantitati
Falsification: If no significant correlation exists between glucosylceramide and seeding activity in GBA-PD (r < 0.3 or p > 0.05), or if idiopathic PD shows equivalent correlation, then glucosylceramide is not a spe
▸Metadatasource: v1_phase_c_backfill · origin_type: audit_hypothesis_generator
| source | v1_phase_c_backfill |
| origin_type | audit_hypothesis_generator |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.